Full-Time
Senior Manager
Marketing, Knee Replacement
Posted on 12/13/2025
Stryker
10,001+ employees
Manufactures orthopedic and surgical medical devices
No salary listed
Belmont, Australia + 4 more
More locations: Brisbane QLD, Australia | Maroochydore QLD, Australia | Melbourne VIC, Australia | Sydney NSW, Australia
Hybrid
Hybrid role with up to 30% travel; expect on-site work at APAC locations.
 Growth & Marketing (1) |
|---|
- Bachelor’s degree required.
- Fluent in English.
- 10+ years of work experience required.
- Influence and develop commercial and marketing strategies with regional and divisional leads that deliver accelerated knee portfolio market share in APAC.
- Responsible for management of the knee portfolio across APAC, including planning and executing targeted and disciplined product launches, developing and maintaining portfolio roadmaps, inputting to divisional New Product development, NPD, and building strong relationships with APAC key opinion leaders and organizations to build differentiating value propositions for knee products and services.
- Help APAC markets identify and execute a focused growth plan for Knees – including implants and software.
- Determine and pursue a winning Knee product portfolio for APAC markets that will drive market growth across our implant businesses.
- Champion the needs and potential of the APAC region with the Joint Reconstruction division to deliver increased value to APAC customers and help accelerate Knee growth across APAC.
- Continually monitor market size, share and trends to make recommendations on market opportunity and strategic focus areas for Stryker. Collate and communicate the APAC market fact base.
- Interpret competitive landscape and incorporate into marketing strategy. Gain market insights through voice of customer with APAC teams, customers, key opinion leaders and organizations. Translate insights into future business strategy, including NPD and business development, proactively partner with markets to adjust strategy based on changes to healthcare environments or new voice of customer.
- Ensure Knee pricing strategies align with overall business goals and profit and loss drivers, to maximise the value delivered by the portfolio and drive accretive margin to the profit and loss.
- Author and drive execution of key strategy documents for portfolio: strategic plan, annual marketing plan, product launch commercialization plans including establishing metrics and goals/success criteria and milestones.
- Develop APAC wide Commercialization/Annual Marketing Plans that demonstrate the size of opportunity aligned to strategic growth areas and the tactics to deliver on the opportunity. Communicate plans with markets and division to ensure opportunities are well understood and key stakeholders are aligned to execution plans.
- Partners with Division and APAC markets to develop, communicate, and execute product life cycle management strategies. Lead product life cycle management of the portfolio across APAC from launch to obsolescence.
- Maintain and collate the 10-year portfolio strategy/plan for the region across, with clear revenue ramps for new product launches, including required investments, resources, market share growth targets, along with market ready & commercial launch timelines.
- Partners with the APAC training team to develop & deliver internal and external education and customer engagement programs, that deliver enhanced capability, confidence and connect our customers to drive advocacy and brand loyalty, while building product knowledge excellence and clinical and procedural understanding.
- Help to build the capability of the local APAC marketing teams, by driving a focus on increasing go to market / marketing excellence in the region, via the Big Picture frameworks, fact base market insights, annual marketing plans, commercialization plans and products launch execution.
- MBA preferred.
- 7+ years medical device/medtech or marketing/sales experience preferred.
- Fluent in additional APAC language desirable.
- Demonstrated proficiency in Microsoft Office (Excel, Word & PowerPoint)
Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kalamazoo, Michigan
Founded
1941
Simplify's Take
What believers are saying
- Robotic surgery leadership drives double-digit sales growth through 2025.
- India Trident II launch targets aging population's rising hip surgeries.
- Peripheral vascular expansion via IVL meets growing arterial disease demand.
What critics are saying
- Handala cyberattack on March 11 delays ortho supply chain 3-6 months.
- Zimmer Biomet Persona IQ erodes ortho share with real-time analytics.
- J&J Velys captures 25% more knee procedures from Mako in 6-12 months.
What makes Stryker unique
- Stryker holds 39.1% US market share in orthopedic product manufacturing.
- Trident II Acetabular System integrates Mako SmartRobotics for hip replacements.
- Amplitude Vascular Systems acquisition adds CO₂ IVL for peripheral arteries.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical & prescription plans
Supplemental health benefits
Flexible Spending accounts
Employee Assistance Program
Short-term & long-term disability
Tuition reimbursement
401(k) plan
Employee Stock Purchase Plan
Company News
Distalmotion targets ASC gynecology programs with new FDA filing Distalmotion has submitted a 510(k) application to the FDA seeking to expand the label of its Dexter robotic surgery system into additional gynecological indications, the company announced April 1. The filing covers sacrocolpopexy, sacrocervicopexy and endometriosis resection. Sacrocolpopexy and sacrocervicopexy are procedures used to treat pelvic…
Stryker Corporation has signed a definitive agreement to acquire Amplitude Vascular Systems, a Boston-based medical technology company developing next-generation intravascular lithotripsy technology for treating calcified peripheral arterial disease. Financial terms were not disclosed. AVS's technology uses pulsed CO₂-generated pressure waves delivered through a balloon catheter to fracture calcium deposits. The platform aims to enhance catheter deliverability, treatment speed and therapy efficiency. The acquisition will strengthen Stryker's peripheral vascular portfolio and expand its presence in arterial disease treatment. Stryker CEO Kevin Lobo said the deal advances the company's vision to build a comprehensive peripheral vascular platform addressing significant clinical needs. IVL technology is experiencing strong growth as physicians increasingly adopt it for calcium modification in complex cardiovascular procedures. The transaction remains subject to customary closing conditions.
Stryker has raised $120 million in a Series C round led by Ribbit Capital, valuing the medical technology company at $1.45 billion. The funding comes despite shares declining 7.6% over the past six months, outperforming the industry's 19.7% drop. The company delivered 11% organic sales growth in Q4 2025 and 10.3% for the full year, marking its fourth consecutive year of double-digit growth. Performance was broad-based across its Orthopaedics, MedSurg and Neurotechnology segments, driven by strong procedural volumes and favourable demographics. Stryker achieved over 100 basis points of operating margin expansion for the second consecutive year despite tariff pressures. The company enters 2026 with a robust capital equipment backlog, though rising interest costs and tariffs present near-term challenges. Analysts maintain a Hold rating on the stock.
Stryker shares fell 9% to $339 following a destructive cyberattack by Iranian-linked group Handala that wiped over 200,000 systems and disrupted manufacturing and shipping operations across 56,000 employees in 61 countries. The medical technology company confirmed disruptions to order processing but stated there was no indication of ransomware. Unlike typical ransomware attacks, this wiper attack permanently deleted data rather than holding it for ransom, complicating recovery efforts. The incident threatens Stryker's 8% to 9.5% organic growth guidance for 2026 if operations fail to normalise quickly. Stryker generated $25 billion in revenue in 2025 with $4.283 billion in free cash flow and holds $4 billion in cash. Analysts maintain a consensus price target of $424.89 with 22 buy ratings and no sell ratings among 30 covering analysts.
Stryker reported Q4 revenues of $7.17 billion, up 11.4% year-over-year and exceeding analyst expectations by 0.8%. The medical device manufacturer, which impacts over 150 million patients annually through its orthopaedics, surgical tools, neurotechnology and patient care solutions, delivered what CEO Kevin Lobo called "an outstanding finish to 2025". The company achieved double-digit sales and adjusted earnings per share growth for both the quarter and full year, whilst expanding adjusted operating margin by at least 100 basis points for the second consecutive year. Across the medical devices and supplies sector, the six diversified stocks tracked reported mixed Q4 results. As a group, revenues beat consensus estimates by 1.9%, though share prices have declined an average of 5.1% since the latest earnings announcements.